News & Comment

Glyscend Therapeutics is developing first-in-class polymer drugs that uniquely interact with the gut wall to treat metabolic and chronic conditions. The company’s lead candidate, GLY-200, is advancing into phase 2 clinical studies for the treatment of type 2 diabetes.

First Republic Bank’s relationships in the sector help it meet the unique needs of both startups and seasoned life science companies.

Many biotechs completed private financing rounds during Autumn which focused on immunotherapy development and more.

Companies developing microbiome-based therapies have been beset by challenges in the past few years, but hopes remain for some applications and could soon be boosted by the first regulatory approval in the field.

Cell and gene therapy companies continue to attract large deals in 2022, despite the financing landscape looking gloomier than in the previous year.

Solarea Bio is harnessing the diversity of the edible plant microbiota to deliver medical food products that aid the dietary management of inflammatory disorders and support healthy aging.

How a 100-year-old study spawned a novel class of multifunctional neurological treatments.

With Exeliom Biosciences’s drug candidate, EXL01, the long-touted immune-modulation potential of a key gut bacterial species is finally reaching patients in the clinic.

Microbiotica’s platform makes it a leader in precision clinical discovery of novel microbiome-based therapeutics and biomarkers. With the platform validated at scale, and a pipeline of programs, the company is open to collaborations in both therapeutic and biomarker discovery.

Using innovative particle-engineering technology, Alveolus Bio is developing a platform that delivers live biotherapeutic products deep into the lungs for the treatment of chronic and infectious respiratory disease.

Australia’s Microba is leveraging its world-leading microbiome tools and data science for rigorous hypothesis-driven live-biotherapeutics development.

Minaris Regenerative Medicine is developing large-scale 3D cell-production processes and optimizing its culture parameters, as well as enabling in-house batch certification, to enable its partners to realize the huge potential of cell therapies.

Shape Therapeutics is developing next-generation gene-therapy technologies that harness the power of artificial intelligence and RNA editing to repair disease-causing mutations.

Asgard Therapeutics is moving cancer immunotherapy forward with an off-the-shelf direct cell reprogramming platform that turns cancer cells into immunogenic dendritic cells that induce potent anticancer immunity.

Precision BioSciences is transforming drug development for new, potentially first- and best-in-class cell and gene therapies with its proprietary ARCUS gene-editing platform, which is derived from a small, naturally occurring DNA-editing nuclease.

Regenerative medicine company Locate Bio is aiming to transform the musculoskeletal market with its range of therapeutic orthobiologic products.

By coupling Twist Bioscience’s DNA-writing technology with expertise in antibody engineering, Twist Biopharma can accelerate the development of new biologics and cell therapies.

With a focus on detecting, intercepting, treating, and ultimately curing cancer, Janssen Oncology is advancing science and solutions in hematologic malignancies and solid tumors through an innovative strategic partnering approach.

GE Healthcare is developing radiopharmaceuticals that can match the most appropriate treatment to a patient, which will help physicians initiate a beneficial treatment regime and could reduce the time that a patient receives an ineffective therapy.

Hayashibara is exploring the potential of the saccharide, trehalose, to advance progress in the development of new medical and therapeutic applications, with a particular focus on its ability to stabilize exosomes and improve drug delivery.